Matthew Cortese

Medical Oncology and Hematology

Cancers Treated:

Specializing In:

Clinical trial design Lymphoid malignancies

About Matthew Cortese


As a lymphoma specialist, I treat all forms of lymphoma, but have a primary clinical and research focus in CLL/SLL and B-cell Non-Hodgkin Lymphomas.  My research focus is to develop a better understanding of the mechanisms of treatment resistance for many lymphomas, as well as to investigate the molecular mechanisms by which low-grade lymphomas transform into more aggressive high-grade lymphomas (e.g. Richter Transformation), in an effort to optimize treatments and provide more detailed prognostic information. 

I am actively involved in clinical trial design and implementation (including novel cellular and targeted therapies), in ongoing efforts to provide better treatments and hope to our patients.  I was born and raised in Upstate New York, and am honored and privileged to be able to provide care as part of an outstanding team here at Roswell Park.


Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine, Lymphoma
  • Department of Cancer Genetics & Genomics


Education and Training:

  • 2011-2016 - MD - State University of New York Upstate Medical University, Syracuse, NY
  • 2013-2016 - MPH with a focus on Health Policy and Program Development - Syracuse University and State University of New York Upstate Medical University, Syracuse, NY


  • 2016-2019 - Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH


  • 2019-2022 - Hematology/Oncology, Cleveland Clinic Foundation, Cleveland, OH

Board Certification:

  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Medical Specialties

Professional Memberships:

  • American Society of Hematology (ASH)
  • American Society of Clinical Oncology (ASCO)
  • American Society for Transplantation and Cellular Therapy (ASTCT)
  • American Medical Association (AMA)

Clinical Trials


Cortese MJ, Wei W, Cerdeña S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. Leukemia & Lymphoma. 2022 Nov 1:1-2.

Cortese MJ, Sauter C. A “CRISPR” non-viral manufacturing approach for CAR T cell therapies. Molecular Therapy. 2022 Oct 20.

George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, Zhao J, Anwer F. Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review. Clinical Lymphoma Myeloma and Leukemia. 2021 Nov 1;21(11):741-51.

Granat LM, Singh AD, Cortese MJ, Velez V, Lichtin A. Severe thrombocytopenia in a patient with otherwise asymptomatic COVID-19. Cleveland Clinic Journal of Medicine. 2021 Feb 1;88(2):86-92.

Cortese MJ, Wei W, Cerdena S, Watkins M, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Grover NS, Snow A. A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. Blood. 2020 Nov 5;136:32-4.

Sohail MA, Li H, Wei W…Cortese MJ…Hill BT, Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. Blood. 2020 Nov 5;136:24-5.

Cortese MJ, Wei W, Hill BT. Outcomes of Active Surveillance Versus Initial Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients. Blood. 2020 Nov 5;136:29-30.

Radakovich N, Cortese MJ, Nazha A. Acute myeloid leukemia and artificial intelligence, algorithms and new scores. Best Practice & Research Clinical Haematology. 2020 Sep 1;33(3):101192.

Haarer B, Mi-Mi L, Cho J, Cortese MJ, Viggiano S, Burke D, Amberg D. Actin dosage lethality screening in yeast mediated by selective ploidy ablation reveals links to urmylation/wobble codon recognition and chromosome stability. G3: Genes, Genomes, Genetics. 2013 Mar 1;3(3):553-61.